Thus, despite the intimate relationship between PARP and PARG activities, and despite the complexities described above, a differential sensitivity clearly manifests across multiple cell lines, indicating that PARG inhibitors may offer an alternative therapeutic option to target a subset of ovarian cancers, such as HRP tumours that are less likely to respond to PARPi. This evidence concerns the gene PARP1 and ovarian carcinoma.